Our services are centred around intellectual property that can be registered. We protect innovation, design, and branding across all sectors of industry, and at all stages in the supply chain.

For each IP right we offer services covering strategic advice, pre-registration searches, registrations and renewals, oppositions and dispute resolution. We handle work throughout the world, working with local colleagues in over 100 countries.


Our attorneys specialise in one or more sectors of industry, which enables them to provide quality advice with a commercial focus.

Our patent specialists have detailed understanding of the background technology, which ensures that your patent applications are prepared with the correct scope, reducing the likelihood of challenges from third parties and objections from the patent office.

They also advise whether other forms of protection would be more appropriate. Our brand specialists work with brand managers for leading brands and their advice is commercially focussed making sure that you get the best value from your budget.

Unitary Supplementary Protection Certificates – a new IP right?


In previous articles we have discussed the ongoing developments to bring the Unified Patent Court (UPC) and Unitary Patent into effect.

However, one piece of the puzzle that has not yet been solved is how Supplementary Protection Certificates (SPCs), which are national intellectual property rights that can extend patent protection for pharmaceutical and plant protection products for up to five years, will be provided for under the new Unified Patent system.

The European Commission has here published an initiative to put in place a unitary SPC and/or a single procedure for granting national SPCs.

While this may seem in conflict with the current SPC regime, whereby SPCs are administered and managed at national level, the introduction of a unitary SPC or single procedure for granting national SPCs will, according to the commission, “make SPCs more accessible and efficient, and benefit the health sector”. Thus, the proposed regulation is likely to extend the advantages of the Unitary Patent system to SPCs. However, it is worth noting that as with the Unitary Patent system, not all European countries will be taking part, so for countries not participating in the new system, the current national SPC arrangements will continue.

As SPCs are typically used to extend the term of a pharmaceutical company’s “crown jewel” patent rights, the value of this proposed unitary SPC right will be determined by whether big pharma is willing to commit such critical patents to the Unitary Patent system. It will, therefore, be interesting to see how the proposed unitary SPC will complement the Unitary Patent system and work alongside existing national rights, and accordingly, whether pharmaceutical patent applicants will file applications for Unitary Patents.

Although a unitary SPC and/or a single procedure for granting national SPCs is looking likely, the initiative is currently in the “call for evidence” stage with the feedback period open from 8 March 2022 until 5 April 2022. However, commission adoption of the initiative is currently planned for the first quarter of 2022, therefore we will not have to wait long for further developments.

This article is for general information only. Its content is not a statement of the law on any subject and does not constitute advice. Please contact Reddie & Grose LLP for advice before taking any action in reliance on it.

Saved Staff
Staff member

Remove all

Call +44 (0)20 7242 0901
Call +44 (0)1223 360 350
Call +49 (0) 89 206054 267
Call +(00) 31 70 800 2162
This field is for validation purposes and should be left unchanged.